[go: up one dir, main page]

WO2002002591A2 - Peptides a utiliser dans des milieux de culture - Google Patents

Peptides a utiliser dans des milieux de culture Download PDF

Info

Publication number
WO2002002591A2
WO2002002591A2 PCT/US2001/017943 US0117943W WO0202591A2 WO 2002002591 A2 WO2002002591 A2 WO 2002002591A2 US 0117943 W US0117943 W US 0117943W WO 0202591 A2 WO0202591 A2 WO 0202591A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
peptide
peptides
library
amino acid
Prior art date
Application number
PCT/US2001/017943
Other languages
English (en)
Other versions
WO2002002591A3 (fr
Inventor
Perry D. Haaland
Douglas B. Sherman
Robert L. Campbell
Walter William Stewart
Sheila A. Lloyd
Bruce Wayne Erickson
Original Assignee
Becton, Dickinson And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton, Dickinson And Company filed Critical Becton, Dickinson And Company
Priority to EP01941853A priority Critical patent/EP1317475A2/fr
Priority to JP2002507843A priority patent/JP2004519417A/ja
Priority to AU2001275173A priority patent/AU2001275173A1/en
Publication of WO2002002591A2 publication Critical patent/WO2002002591A2/fr
Publication of WO2002002591A3 publication Critical patent/WO2002002591A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells

Definitions

  • the invention relates to peptides which affect cells in culture and to methods for discovery and manufacture of such peptides.
  • the invention relates to peptides which affect growth of cells in culture and peptides which affect cellular protein production.
  • Tissue and protein hydrolysates have been routinely used as a source of peptides in cell culture media since the late 1800's. They are the most common undefined culture media component in present use in bacteriology and often replace serum in mammalian culture (S. Saha and A. Sen. 1989. Ada Virol. 33:338-343). Hydrolysates and serum are not optimal sources of peptides for culture media, however, because their compositions are undefined and variable, and serum may harbor pathogens such as BSE. It has been recognized that peptides are generally preferred nutrients as compared to their constituent amino acids.
  • casein hydrolyzed by the neutral protease of Micrococcus caseolyticus M. J. Desmazeaud and J. H. Hermier. 1972. Eur. J. Biochem. 28:190- 198
  • a papain digest of glucagon M. J. Desmazeaud and J. H. Hermier. 1973. Biochimie 55:679- 684
  • trypsin digested ⁇ -casein enhances the growth of the genus Bifidobacterium (M. Poch and A. Bezkorovainy. 1991. J.
  • FR:013 discloses relatively simple mixtures of tetrapeptides in which the N- and C-terminal residues are fixed and any one of three residues occur at each position in between.
  • Fodor, et al. (1991. Science 251:767-773) teach solid phase peptide synthesis on slides, using predetermined amino acids coupled to defined areas of the slide using photomasks. In this way an array of 1024 different peptides with defined C-termini was synthesized. All of these techniques attempt to circumvent the individual screening of millions of peptides and to increase the amount of a given sequence in the library to simplify screening and identification of biologically active peptides.
  • the present invention employs a peptide library approach to select and identify peptides which meet these needs, in particular a process that links discovery and manufacturing of peptides which affect cell growth (either positively or negatively) or which enhance or inhibit cellular protein production.
  • the present invention provides peptide libraries which are useful for rapid identification of biologically active compounds which affect the properties of cells in culture.
  • the present invention further provides peptides identified in these libraries, which include cell growth enhancing peptides, cell growth inhibiting peptides and peptides which enhance or inhibit production of cellular proteins, particularly production of ⁇ -toxin by Clostridium perfringens.
  • Once the sequence of a peptide having the desired biological activity is identified it may be produced in large quantity (e.g., by chemical synthesis or expression of recombinant DNA) and formulated in a culture medium to produce the desired effect on cultured cells.
  • the libraries of the invention and the peptides identified in them are particularly useful in certain large-scale, economical recombinant production methods. DETAILED DESCRIPTION OF THE INVENTION
  • a limited diversity peptide library was constructed using conventional techniques for peptide synthesis and was subsequently screened for biologically active peptides exhibiting certain desired characteristics.
  • the initial goal was to identify peptides which could be included in culture media to increase the amount of ⁇ -toxin produced by C. perfringens, either by increasing cell growth (i.e., cell number) or by increasing the amount of toxin produced per cell.
  • the library of initial candidates was based on several design criteria. First, it is known that proteose peptone is a preferred hydrolysate for culturing C. perfringens.
  • Proteose peptone is manufactured using pepsin, so leucine would be one of the more common C-termini in the peptides of the hydrolysate. Accordingly, a tetrapeptide library was constructed with leucine as the C-terminus (the fourth position of the peptide) and alanine (a simple amino acid) in the third position as a spacer.
  • the ten Selected Amino Acid Group Representatives shown below, each representing a group of related amino acids, were selected for insertion at the remaining first two positions of the peptides. Selection of the group representative amino acid is typically based on ease of peptide synthesis using that amino acid.
  • XXAL library This library is referred to as the XXAL library, with "X” indicating an amino acid selected to represent a cluster group.
  • Peptides for the peptide library may be synthesized by any suitable method known in the art, such as FMOC chemistry of Atherton and Sheppard (1989) in solid phase peptide synthesis (Merrifield, 1965). Boc chemistry may also be used as well as synthesis on a variety of different solid supports, "tea-bag” synthesis (Houghten), and split and divide combinatorial methods. Solution phase methods for peptide synthesis may also be used.
  • the library peptides may include modifications to the C- terminus (e.g., amides and esters), the N-terminus (e.g., acetyl) and non-naturally occurring amino acids (e.g., norleucine) to assess the effect of such modifications on peptide activity.
  • modifications to the C- terminus e.g., amides and esters
  • the N-terminus e.g., acetyl
  • non-naturally occurring amino acids e.g., norleucine
  • the library is screened in a growth assay.
  • the selected cells are first grown in appropriate culture media without peptide supplement, then subcultured in media supplemented with each of the library peptides.
  • the screening medium may be a complex medium for the selected cell type, but is preferably a defined medium to allow evaluation of peptide effects without interference from undefined materials present in the medium. It is also preferable to optimize the base medium for cell growth prior to peptide screening, although unoptimized media may also be used.
  • growth of C. perfringens in the presence and absence of the peptides was evaluated in a basal medium rich in amino acids and containing the necessary vitamins, metals, and simple carbon source.
  • the library is screened in an assay appropriate for detection of that cell product.
  • the selected cells are first grown in appropriate culture media without peptide supplement, then subcultured in media supplemented with each of the library peptides.
  • the screening medium may be a complex medium for the selected cell type, but is preferably a defined medium to allow evaluation of peptide effects without interference from undefined materials present in the medium. It is also preferable to optimize the base medium for protein expression prior to peptide screening, although unoptimized media may also be used.
  • a particular goal of the present work was to identify peptides which affect ⁇ -toxin production by Clostridium perfringens.
  • ⁇ -toxin secreted from the cell was quantitated in a sandwich ELISA assay using two mouse anti- ⁇ - toxin monoclonal antibodies followed by a goat anti-mouse IgG2A conjugated to horse radish peroxidase (HRP).
  • HRP horse radish peroxidase
  • Toxin was quantitated by serial dilution of the cultures and compared to toxin produced by cultures which did not contain added peptide (base media cultures). Absorbance was read at 492 nm and the B 50 values (the dilutions at which the A492 signal is 50% of the maximum signal) were calculated and averaged for replicate cultures. To obtain the total toxin production value the reciprocal of the B 50 value was multiplied by the OD 6 oo.
  • Toxin per cell was expressed as toxin/OD.
  • ELISA assay formats are easily adapted for detection of other cell products for which monoclonal antibodies or other specific binders or ligands are available or can be generated.
  • other immunoassay formats may be employed to quantify ⁇ - toxin or other products of interest. These include radioimmunoassay (RIA), direct ELISA, ELISA's using other indicating enzymes, ELISA's using fluorescent reporter molecules and flow-through assays such as those which employ surface plasmon resonance detection.
  • RIA radioimmunoassay
  • direct ELISA direct ELISA
  • ELISA's using other indicating enzymes ELISA's using fluorescent reporter molecules
  • flow-through assays such as those which employ surface plasmon resonance detection.
  • the ELISA results for ⁇ -toxin were confirmed in a bioassay.
  • GEAL SEQ ID NO:l
  • KLAL SEQ ID NO:2
  • SEQ ID NO:3 was so inhibitory to growth that the stage II culture did not reach 1 OD, the minimum requirement for proceeding to testing in stage III.
  • the constituent amino acids of SEQ ID NO:l and SEQ ID NO:2 produced no significant difference in growth as compared to the base medium alone.
  • EKAL SEQ ID NO:3 also substantially enhanced growth in both crude form (2X improvement in growth) and purified form (3.5X improvement in growth).
  • ESAL (SEQ ID NO:4) was also found to enhance growth in both crude and purified form. The fact that similar results were observed with both crude and purified peptides indicates that the peptide itself, and not a minor chemical involved in peptide processing, is responsible for the effect.
  • Toxin production in response to the peptides in the XXAL library was evaluated using 15 hr. growth and two-point ELISA values. Toxin data was collected on 75 of the 100 peptides in this library and the number of replicates per tetramer ranged from 1-14. Total toxin ratio was calculated as the quotient of the total toxin derived for media containing test peptide divided by the base media total toxin value. It was found that VNAL (SEQ ID NO:8), SNAL (SEQ ID NO:7), DKAL (SEQ ID NO: 14), and NDAL (SEQ ID NO:5) increased the total toxin ratio. LSAL (SEQ ID NO: 15) did not have an effect on growth, however, it significantly inhibited toxin production.
  • the XXAL limited diversity library was rationally designed based on the predominant C-termini found on peptides in the best-performing hydrolysate for growth of the selected cell type. This concept can be extended to design of other libraries to be screened for peptides affecting a variety of cells.
  • the following table illustrates the C- and/or N-termini of peptides preferred for construction of libraries to be screened for compounds which affect the growth of cells which prefer culture in the presence of hydrolysates prepared with the indicated enzyme or chemical reagent.
  • V8 protease D or E endoproteinase Asp-N D enzyme (cleaves on the N- terminal side of D)
  • all amino acids in a particular group may be placed in positions 1 and 2, or in all non-C-terminal positions of the tetrapeptide.
  • the letter Z is used to represent any one of the possible amino acid residues such libraries would be described as, for example, ZZAL and ZZZL.
  • the C-terminal amino acid may be any of the residues associated with known enzymatic or chemical cleavage of proteins.
  • peptide KKAL As the library evolved from XXAL to ZZAL the following peptides were found to significantly enhance cell growth: NDAL (SEQ ID NO:5), NNAL (SEQ ID NO:6), SNAL (SEQ ID NO:7) and VNAL (SEQ ID NO:8). In contrast, peptide KKAL (SEQ ID NO:9) inhibited cell growth.
  • EKAL SEQ ID NO:3
  • DKAL DKAL
  • FEFVG (SEQ ID NO: 16) had the second highest mean of the peptides tested for total toxin production (8.79) and its effect was found to be highly reproducible over multiple experimental repetitions. Further statistical analysis of SEQ ID NO: 16 demonstrated that its mean for total toxin production was statistically significantly higher than the means below 7.
  • optimized base medium a defined synthetic medium which does not contain hydrolysate
  • SEQ ID NO: 16 enhanced growth by about 40% as compared to the optimized base medium alone, while addition of its constituent amino acids to the medium (F, E, V, G) increased growth only about 15%.
  • SEQ ID NO: 16 increased total toxin in the two-point ELISA by about 2.2x over total toxin production in the optimized base medium alone, while addition of the constituent amino acids resulted in total toxin production approximately equivalent to the base medium alone. It was also found that in commercial media containing 3.5% hydrolysate blend, SEQ ID NO: 16 doubled the amount of toxin produced per cell but did not increase growth. This accounted for a near doubling of total toxin produced by the culture with little or no increase in cell number. This is a particularly desirable outcome for pharmaceutical companies, as the increase in toxin is obtained without the need to process additional cell mass.
  • the ten pentamers with the highest mean total toxin production were FSLLE (SEQ ID NO: 17, 8.855), FEFVG (SEQ ID NO:16, 8.786611), FSFVE (SEQ ID NO:18, 8.727), NEYLY (SEQ ID NO:19, 8.665) , FDIST (SEQ ID NO:20, 8.395), NLTEL (SEQ ID NO:21, 8.321), SQLEL (SEQ ID NO:22, 8.28375), ETLNL (SEQ ID NO:23, 8.28), NQLEV (SEQ ID NO:24, 7.81) and IKLAS (SEQ ID NO:25, 7.7475).
  • HTVEL (SEQ ID NO:26), QNDVY (SEQ ID NO:27), LPDLF (SEQ ID NO:28), DTHHI (SEQ ID NO:29), FVPEK (SEQ ID NO:30), GYPEV (SEQ ID NO:31), HAPAY (SEQ ID NO:32), SNGIY (SEQ ID NO:33), KFIEK (SEQ ID NO:34), MHAPP (SEQ ID NO:35), MPNNF (SEQ ID NO:36), PELME (SEQ ID NO:37), FMSTA (SEQ ID NO:38), VNVQA (SEQ ID NO:39), KFIFE (SEQ ID NO:40), PLFEQ (SEQ ID NO:41), MMELE (SEQ ID NO:42), ALFHE (SEQ ID NO:43), YEQQN (SEQ ID NO:44), GGMPG (SEQ ID NO:45), SYIME (SEQ ID NO:46) and YEYIY (SEQ ID NO:47) also
  • VHVYQ (SEQ ID NO:67) and NNNNN (SEQ ID NO:68) resulted in toxin production above the mean obtained in 0.5% hydrolysate media.
  • YEYIG (SEQ ID NO:69) in 0.5% hydrolysate media produced a total toxin mean value greater than twice that obtained using 3.5% hydrolysate alone.
  • Peptides identified in the XXXX library space were also found to inhibit growth of C. perfringens 1 .
  • SKKA SEQ ID NO:10
  • KGLK SEQ ID NO:ll
  • VKKG SEQ ID NO:12
  • GLKK SEQ ID NO: 13
  • the pentamer FEFVG (SEQ ID NO:16) was modified to form the hexamers EFEFVG (SEQ ID NO:74), NFEFVG (SEQ ID NO:75), FEFVGG (SEQ ID NO:76), FEFVGE (SEQ ID NO:77) and FEFVGY (SEQ ID NO:78), which produced total toxin values ranging from 6 to 9.7 as compared to the base media alone which had a mean total toxin of 3.82. Cell growth in chemically defined media is typically slower than in hydrolysate based media.
  • peptides were found to enhance growth in chemically defined base media sufficiently to equal growth in traditional hydrolysate based media. These peptides include VFTDK (SEQ ID NO:79), LTKVD (SEQ ID NO:80), LLPKT (SEQ ID NO:81), PLTGG (SEQ ID NO:82), GGTPV (SEQ ID NO:83), PKGTV (SEQ ID NO:84), DDDDD (SEQ ID NO:85), KLGVK (SEQ ID NO:86), TPKTL (SEQ ID NO:87), GDVTK (SEQ ID NO:88), HPAFE (SEQ ID NO:89), FFPTD (SEQ ID NO:90), VNYQA (SEQ ID NO:91) and IILEA (SEQ ID NO:92) which all produced mean growth values of 4 at 4 hours.
  • the chemically defined screening media alone had a mean of 3.2 OD for growth at 4 hours.
  • ESALD SEQ ID NO:93
  • ESALD also enhanced growth over the base media.
  • Peptides identified as having the desired properties may be produced by a variety of methods in quantities sufficient for commercial or research use.
  • the peptides may be chemically or enzymatically synthesized as is known in the art, however, more preferably the peptides are produced using methods for expression of recombinant nucleic acids encoding the peptides.
  • the selected peptide sequence is first converted to a corresponding nucleic acid sequence which encodes the amino acid sequence of the peptide. This may be an RNA sequence which is subsequently translated to produce the peptide, or it may be a DNA sequence which is then cloned into an expression vector under the control of a promoter which enables the transcription of the DNA sequence with subsequent translation of the mRNA.
  • peptides may be purified, if necessary, also using standard methods for physical, chemical and affinity separation which are well-known to the practitioner.
  • the peptides of the invention comprise C-termini or N-termini corresponding to the C-termini and N-termini produced by enzymatic or chemical cleavage of proteins in traditional culture media hydrolysates.
  • This facilitates recombinant production of the peptides, typically in bacteria or yeast, using concatemer constructs as are known in the art.
  • Concatemers may contain hundreds of copies of the coding sequence.
  • Concatemer nucleic acid constructs encoding peptides of the invention with C-termini or N-termini which are subject to enzymatic or chemical cleavage produce polypeptides comprising repeating subunits of the peptide amino acid sequence separated by convenient cleavage sites.
  • Cleavage using the appropriate enzymatic or chemical means releases the peptide monomer.
  • This approach to manufacture increases the yield of the desired peptide and decreases manufacturing costs.
  • Post-expression processing is simplified due to the cleavage site which is automatically produced by cloning of the concatamer structure.
  • the peptide NDAL (SEQ ID NO:5) was quickly discovered using the XXAL library approach and can be efficiently manufactured using the concatamer strategy with subsequent cleavage using pepsin or the endopeptidase N-ASN.
  • the growth inhibitor KKAL (SEQ ID NO:9) could also be manufactured using the concatamer strategy and cleavage with pepsin.
  • FSFVE FSFVE (SEQ ID NO: 18) could be expressed as a concatamer and cleaved into monomers following expression using the V8 protease.
  • HTVEL SEQ ID NO:26
  • QNDVY SEQ ID NO:27
  • These peptides could be expressed from the same concatamer minigene, cleaved by pepsin into peptides and used without further separation since both exhibit the same attribute.
  • Such a combination minigene may also be useful when one peptide is needed to balance another. For example, alternating a basic sequence with an acidic sequence may make the total minigene product compatible with the host cell.
  • Combination minigenes may also be useful production vehicles when multiple peptides exhibiting different attributes are desired for formulation into the same medium. In this case, all the necessary peptides may be expressed, processed and formulated in a single production process without the need to separate the individual peptides.
  • FEFVG SEQ ID NO:16
  • FEFVG can be cloned as a concatamer with a nonsense sequence spacer between each peptide coding sequence to permit liberation from the concatamer.
  • the coding sequence for the nonsense peptide DEEP could flank the sequence coding for the media enhancer peptide, and the concatamer could be cleaved with the endoproteinase Asp-N (which cuts before aspartic acid) and proline endopeptidase (which cuts after proline).
  • This approach requires multiple reagents and the spacer may need to be separated from the desired peptide if it is not compatible with the cell culture.
  • Nonsense spacers may also be used between peptide coding sequences in the concatemer to generate cleavable sites and facilitate processing in otherwise non-cleavable peptide sequences.
  • the preferred use of the peptides of the invention is in cell culture media (including media for culture of cells and tissues derived from prokaryotes and eukaryotes, vertebrates and invertebrates) to produce a desired effect on the cells. Such effects may include increased or decreased growth rate, increased or decreased production of a cell product, or increased or decreased response to a substance in the environment (e.g., a hormone).
  • the base culture medium to which the peptide is added may be a chemically defined medium or a complex medium containing undefined components such as fetal calf serum (FCS) or yeast hydrolysate. Chemically defined or semi-defined media are preferred, as the peptides of the invention are most advantageously used as a means for reducing or eliminating performance variability due to undefined media components and for reducing or eliminating animal-derived components in media used to produce pharmaceutical products.
  • a selected peptide is typically added to the culture medium at a concentration from about 0.1-25 mM more preferably from about 1.0 and 12 mM. However, it is within the ordinary skill in the art to determine an appropriate concentration of an inventive peptide in a selected culture medium. Multiple peptides may be added to the culture medium to produce a synergistic effect (if both have the same effect on the cells) or to produce multiple effects (if each peptide has a different effect on the cells).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des bibliothèques de peptides qui servent à identifier rapidement des composés biologiquement actifs. L'invention concerne en outre des peptides qui comportent des peptides affectant la croissance cellulaire, et des peptides qui renforcent ou inhibent la production de protéines cellulaires. Nombre de ces peptides peuvent être produits en grande quantité par des techniques de recombinaison et formulés dans un milieu de culture afin de produire l'effet voulu sur des cellules et tissus cultivés. Selon l'invention, certaines de ces bibliothèques et les peptides qui y ont été identifiés sont particulièrement utiles dans des procédés d'expression de recombinaison à base concatémère.
PCT/US2001/017943 2000-06-30 2001-06-04 Peptides a utiliser dans des milieux de culture WO2002002591A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01941853A EP1317475A2 (fr) 2000-06-30 2001-06-04 Peptides a utiliser dans des milieux de culture
JP2002507843A JP2004519417A (ja) 2000-06-30 2001-06-04 培地用ペプチド
AU2001275173A AU2001275173A1 (en) 2000-06-30 2001-06-04 Peptides for use in culture media

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/608,892 2000-06-30
US09/608,892 US6759510B1 (en) 2000-06-30 2000-06-30 Peptides for use in culture media

Publications (2)

Publication Number Publication Date
WO2002002591A2 true WO2002002591A2 (fr) 2002-01-10
WO2002002591A3 WO2002002591A3 (fr) 2003-03-20

Family

ID=24438499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/017943 WO2002002591A2 (fr) 2000-06-30 2001-06-04 Peptides a utiliser dans des milieux de culture

Country Status (5)

Country Link
US (6) US6759510B1 (fr)
EP (1) EP1317475A2 (fr)
JP (1) JP2004519417A (fr)
AU (1) AU2001275173A1 (fr)
WO (1) WO2002002591A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044045A3 (fr) * 2001-11-19 2004-08-05 Becton Dickinson Co Peptides promouvant l'adherence, la croissance et la secretion des cellules
US7074615B2 (en) 2003-08-15 2006-07-11 Becton, Dickinson And Company Peptides for enhanced cell attachment and cell growth
US7157275B2 (en) 2003-08-15 2007-01-02 Becton, Dickinson And Company Peptides for enhanced cell attachment and growth
EP2351833A4 (fr) * 2008-10-28 2013-05-01 Chugai Pharmaceutical Co Ltd Milieu de culture contenant un peptide pour la culture d'une cellule animale
EP2561065B1 (fr) 2010-04-23 2016-11-09 Life Technologies Corporation Milieu de culture cellulaire comprenant des petits peptides
CN107266554A (zh) * 2012-03-19 2017-10-20 麦德林制药私人有限公司 制备重组血管扩张肽的方法、表达构建体、宿主细胞及重组融合多肽

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759510B1 (en) * 2000-06-30 2004-07-06 Becton, Dickinson And Company Peptides for use in culture media
US20080020979A1 (en) * 2006-06-09 2008-01-24 Rapraeger Alan C Peptides of Syndecan-1 For Inhibiting Angiogenesis
US7547760B2 (en) * 2006-07-03 2009-06-16 West Virginia University Peptides and chemical compound for inhibition of SHP2 function
DE102007011912A1 (de) * 2007-03-13 2008-09-18 Sanofi-Aventis Verfahren für das Erzeugen von Peptidbibliotheken und deren Verwendung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586772T2 (de) 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
JPH0474197A (ja) * 1990-07-12 1992-03-09 Naoyoshi Suzuki 新規な免疫調整生理活性ペプチド
AU668347B2 (en) 1990-11-21 1996-05-02 Torrey Pines Institute For Molecular Studies Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
ES2097925T3 (es) * 1991-09-18 1997-04-16 Affymax Tech Nv Metodo para sintetizar diversas colecciones de oligomeros.
ES2170105T3 (es) 1993-10-04 2002-08-01 Pasteur Institut Compuestos que modifican la transmision serotoninergica; aplicaciones diagnosticas y terapeuticas.
US5962634A (en) 1994-07-08 1999-10-05 Thomas Jefferson University IgE antagonists
US5695980A (en) * 1995-06-06 1997-12-09 Human Genome Sciences Polynucleotides, vectors, cells and an expression method for human MutT2
US5972406A (en) * 1995-04-14 1999-10-26 Bioelastics Research Ltd. Bioelastomers suitable as food product additives
US6498138B1 (en) * 1998-03-11 2002-12-24 University Of Southern California Method of promoting production of living tissue equivalents
US6248874B1 (en) * 1998-11-24 2001-06-19 Wisconsin Alumni Research Foundation DNA molecules encoding bacterial lysine 2,3-aminomutase
US7742877B1 (en) * 1999-07-22 2010-06-22 Becton, Dickinson & Company Methods, apparatus and computer program products for formulating culture media
US6759510B1 (en) 2000-06-30 2004-07-06 Becton, Dickinson And Company Peptides for use in culture media

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044045A3 (fr) * 2001-11-19 2004-08-05 Becton Dickinson Co Peptides promouvant l'adherence, la croissance et la secretion des cellules
US7041506B2 (en) 2001-11-19 2006-05-09 Becton Dickinson And Company Peptides promoting cell adherence, growth and secretion
US7344884B2 (en) 2001-11-19 2008-03-18 Becton, Dickinson And Company Peptides promoting cell adherence, growth and secretion
US7074615B2 (en) 2003-08-15 2006-07-11 Becton, Dickinson And Company Peptides for enhanced cell attachment and cell growth
US7157275B2 (en) 2003-08-15 2007-01-02 Becton, Dickinson And Company Peptides for enhanced cell attachment and growth
US7399630B2 (en) 2003-08-15 2008-07-15 Becton, Dickinson And Company Peptides for enhanced cell attachment and growth
EP2351833A4 (fr) * 2008-10-28 2013-05-01 Chugai Pharmaceutical Co Ltd Milieu de culture contenant un peptide pour la culture d'une cellule animale
EP2561065B1 (fr) 2010-04-23 2016-11-09 Life Technologies Corporation Milieu de culture cellulaire comprenant des petits peptides
US10793827B2 (en) 2010-04-23 2020-10-06 Life Technologies Corporation Cell culture medium comprising small peptides
US11365389B2 (en) 2010-04-23 2022-06-21 Life Technologies Corporation Cell culture medium comprising small peptides
EP3165600B1 (fr) 2010-04-23 2022-11-02 Life Technologies Corporation Milieu de culture cellulaire comprenant des petits peptides
CN107266554A (zh) * 2012-03-19 2017-10-20 麦德林制药私人有限公司 制备重组血管扩张肽的方法、表达构建体、宿主细胞及重组融合多肽

Also Published As

Publication number Publication date
US7179635B2 (en) 2007-02-20
US20040265911A1 (en) 2004-12-30
US7267983B2 (en) 2007-09-11
AU2001275173A1 (en) 2002-01-14
US20090124008A1 (en) 2009-05-14
US20050186634A1 (en) 2005-08-25
JP2004519417A (ja) 2004-07-02
WO2002002591A3 (fr) 2003-03-20
US20040265910A1 (en) 2004-12-30
EP1317475A2 (fr) 2003-06-11
US6759510B1 (en) 2004-07-06
US20060088889A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
US20090124008A1 (en) Peptides for use in culture media
Gallop et al. Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries
Margoliash Primary structure and evolution of cytochrome c
Goll et al. Role of the calpain system in muscle growth
Beck et al. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development
Jackson et al. Enzymic cyclization of linear peptide esters using subtiligase
Nachman et al. Leads for insect neuropeptide mimetic development
Higuchi et al. Bradykinin-potentiating peptides and C-type natriuretic peptides from snake venom
Dolle Discovery of enzyme inhibitors through combinatorial chemistry
ZHANG et al. A novel angiotensin I converting enzyme inhibitory peptide from the milk casein: Virtual screening and docking studies
JPH05508321A (ja) ペプチドライブラリィ及びスクリーニングシステム
KR100237126B1 (ko) 펩티드 유사체의 신속한 합성 및 검색방법
Atlas The active site of porcine elastase
Eichler et al. Novel α-glucosidase inhibitors identified using multiple cyclic peptide combinatorial libraries
CN107849737B (zh) 肽文库构建方法及相关载体
Nagasawa et al. Structure and activity of Bombyx PBAN
Richter et al. Biosynthesis of peptides in the skin of Xenopus laevis: isolation of novel peptides predicted from the sequence of cloned cDNAs
AU2006224318B2 (en) Peptide stabilizer compounds and screening method
Kobayakawa et al. Design, synthesis and evaluation of bioactivity of peptidomimetics based on chloroalkene dipeptide isosteres
WO2003106615A3 (fr) Deprotection du soufre apres scission pour synthese convergente de proteine par ligation chimique
Dziuba et al. Chicken meat proteins as potential precursors of bioactive peptides
JPH06510281A (ja) ペプチドアミドの製造
Creutz et al. Pattern of repeating aromatic residues in synexin. Similarity to the cytoplasmic domain of synaptophysin
JPH0616568A (ja) アンジオテンシン変換酵素阻害剤
WO1996018104A1 (fr) Polypeptides apparentes a la melittine, leurs ensembles de melanges et banques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN ES IL JP KR MX NZ RU SG

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001941853

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001941853

Country of ref document: EP